BCTC

Name: BCTC
Brand: MedChemExpress
SKU: HY-19960
Rating: 5.0 (3 reviews)

Cat. No.: HY-19960 Purity: 98.03%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.

For research use only. We do not sell to patients.

BCTC Chemical Structure

CAS No. : 393514-24-4

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 73	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 73	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 66	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 86	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 317	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

3 Publications Citing Use of MCE BCTC

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TRP Channel Isoform Specific Products:

View All Isoforms

TRPC TRPM TRPV TRPA TRPML

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 37.0 nM (CGRP-LI)^[3].
IC50: 36.0 nM (SP-LI)^[3].

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	0.5 nM Compound: 5	Antagonist activity at rat TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by [45Ca2+] uptake assay Antagonist activity at rat TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by [45Ca2+] uptake assay	[PMID: 17489570]
CHO	IC₅₀	0.6 nM Compound: 5	Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by [45Ca2+] uptake assay Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of capsaicin-induced receptor activation by [45Ca2+] uptake assay	[PMID: 17489570]
CHO	IC₅₀	0.7 nM Compound: 5	Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of acid-induced receptor activation by [45Ca2+] uptake assay Antagonist activity at human TRPV1 expressed in CHO cells assessed as blockade of acid-induced receptor activation by [45Ca2+] uptake assay	[PMID: 17489570]
CHO	IC₅₀	0.7 nM Compound: 5	Antagonist activity at rat TRPV1 expressed in CHO cells assessed as blockade of acid-induced receptor activation by [45Ca2+] uptake assay Antagonist activity at rat TRPV1 expressed in CHO cells assessed as blockade of acid-induced receptor activation by [45Ca2+] uptake assay	[PMID: 17489570]
CHO-K1	IC₅₀	0.019 μM Compound: BCTC	Antagonist activity at capsaicin-induced human recombinant TRPV1 expressed in CHO-K1 cells co-expressing aequorin incubated for 2.5 mins in presence of ATP followed by capsaicin addition by luminescence assay Antagonist activity at capsaicin-induced human recombinant TRPV1 expressed in CHO-K1 cells co-expressing aequorin incubated for 2.5 mins in presence of ATP followed by capsaicin addition by luminescence assay	[PMID: 31202991]
HEK293	IC₅₀	0.6 nM Compound: 5	Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as blockade of acid-induced receptor activation by FLIPR assay Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as blockade of acid-induced receptor activation by FLIPR assay	[PMID: 17489570]
HEK293	IC₅₀	0.6 nM Compound: 5	Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as blockade of acid-induced receptor activation by FLIPR assay Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as blockade of acid-induced receptor activation by FLIPR assay	[PMID: 17489570]
HEK293	IC₅₀	1.9 nM Compound: 5	Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as blockade of capsaicin-induced receptor activation by FLIPR assay Antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as blockade of capsaicin-induced receptor activation by FLIPR assay	[PMID: 17489570]
HEK293	IC₅₀	475 nM Compound: BCTC	Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol mediated current amplitude at +80 mV holding potential by whole cell patch-clamp assay Antagonist activity at rat TRPM8 expressed in HEK293 cells assessed as inhibition of menthol mediated current amplitude at +80 mV holding potential by whole cell patch-clamp assay	[PMID: 26847872]
HEK293	IC₅₀	5 nM Compound: 5	Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as blockade of capsaicin-induced receptor activation by FLIPR assay Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as blockade of capsaicin-induced receptor activation by FLIPR assay	[PMID: 17489570]
HEK-293T	IC₅₀	0.15 nM Compound: BCTC	Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of CAP-induced intracellular Ca2+ influx by fluorescence-based assay Antagonist activity at human brain TRPV1 expressed in HEK293T cells assessed as inhibition of CAP-induced intracellular Ca2+ influx by fluorescence-based assay	[PMID: 24484240]
HEK-293T	IC₅₀	2.12 nM Compound: BCTC	Antagonist activity at rat TRPV1 receptor expressed in HEK293T cells assessed as inhibition of temperature-induced calcium flux after 30 mins by Fluo-4AM based fluorescence assay Antagonist activity at rat TRPV1 receptor expressed in HEK293T cells assessed as inhibition of temperature-induced calcium flux after 30 mins by Fluo-4AM based fluorescence assay	[PMID: 23796768]
HEK-293T	IC₅₀	4.86 nM Compound: BCTC	Antagonist activity at rat TRPV1 receptor expressed in HEK293T cells assessed as inhibition of capsaicin-induced calcium flux after 30 mins by Fluo-4AM based fluorescence assay Antagonist activity at rat TRPV1 receptor expressed in HEK293T cells assessed as inhibition of capsaicin-induced calcium flux after 30 mins by Fluo-4AM based fluorescence assay	[PMID: 23796768]

In Vitro

BCTC (20-100 μM; 72 h) shows highly selective antitumor activity in DU145 cells^[1].
BCTC (20-100 μM; 48 h) induces cell cycle arrest in the G0/G1 phase by selectively regulating the expression levels of cell cycle regulatory protein subsets, and doesn’t induce apoptosis^[1].
BCTC (10 μM and 100 μM; 48 h) inhibits cell migration and invasion^[1].
BCTC effectively inhibits the TRPV1 function of rat spinal cord by inhibiting the release of calcitonin gene-related peptide-like immunoreactivity (CGRP-LI) (IC₅₀=37.0 nM) and P-like substance immunoreactivity (SP-LI) (IC₅₀=36.0 nM) induced by capsaicin (300 nM) ^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	DU145
Concentration:	20 μM, 40 μM, 60 μM, 80 μM,100 μM
Incubation Time:	48 h
Result:	Down-regulated p-Akt, while p-GSK-3β was up-regulated leaving their unphosphorylated form unchanged. Significantly down-regulated Cyclin D1(20), the most relevant protein in the cell cycle, without affecting cyclin-B1. Reduced the expression of CDK2 and CDK6, but without affecting the expression level of CDK4. Downregulates MMP2 and p-FAK levels.

Cell Viability Assay^[1]

Cell Line:	DU145, PNT1A
Concentration:	20 μM, 40 μM, 60 μM, 80 μM,100 μM
Incubation Time:	72 h
Result:	Decreased the growth of DU145 cells in a concentration-dependent manner, with 12.03% and 50.69% growth inhibition at 10 µM and 100 µM, respectively, but had little effect on normal prostate PNT1A cells.

In Vivo

BCTC (1-30 mg/kg; Oral gavage; Single dose) can inhibit inflammatory and neuropathic heat pain and mechanical hyperalgesia in Sprague-Dawley rats by targeting VR1, which has analgesic effect^[2].
BCTC (10-100 mg/kg; Oral gavage, Twice daily for 4 weeks) improves the insulin resistance and systemic glucose and lipid metabolism, and increase insulin secretion in diabetic ob/ob mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Capsaicin-induced Sprague-Dawley rats model^[2]
Dosage:	1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration:	Oral gavage (p.o.), Single dose. Before capsaicin (HY-10448) treatment (30 μg; intraplantar injection; Single dose)
Result:	Inhibited capsaicin-mediated thermal hyperalgesia in a dose-dependent manner.

Animal Model:	Freund’s complete adjuvant (FCA) Sprague-Dawley rats model^[2]
Dosage:	1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration:	Oral gavage (p.o.), Single dose. After 100 % FAC treatment (50 μL; intraplantar injection; Single dose)
Result:	Significantly reduced FAC-induced inflammation-related thermal pain and mechanical hyperalgesia, and extended the inhibitory effect of mechanical hyperalgesia to 6 h at high doses (10 mg/kg, 30 mg/kg).

Animal Model:	Partial sciatic nerve ligation Sprague-Dawley rats model^[2]
Dosage:	1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration:	Oral gavage (p.o.), Single dose. After partial sciatic nerve ligation.
Result:	Reduced post-operative abnormal tactile pain and mechanical hyperalgesia in a dose-dependent manner.

Animal Model:	Particularly strong insulin resistance and hyperinsulinemia ob/ob mice model^[5]
Dosage:	10 mg/kg, 30 mg/kg, 100 mg/kg
Administration:	Oral gavage (p.o.); Twice daily for 4 weeks
Result:	Reduced plasma triglyceride and glucose area under the curve (AUC) level. Decreased calcitonin gene-related peptide (CGRP) levels in a dose-dependent manner.

Molecular Weight

372.89

Formula

C₂₀H₂₅ClN₄O

CAS No.

393514-24-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(N1CCN(C2=NC=CC=C2Cl)CC1)NC3=CC=C(C(C)(C)C)C=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (134.09 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6818 mL	13.4088 mL	26.8176 mL
5 mM	0.5364 mL	2.6818 mL	5.3635 mL
10 mM	0.2682 mL	1.3409 mL	2.6818 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.03%

Select Batch:

Data Sheet (282 KB) SDS (393 KB)

COA (247 KB) RP-HPLC (242 KB)

Handling Instructions (2659 KB)

References

[1]. Liu T, et al. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2016 Jan;11(1):182-188. [Content Brief]

[2]. Pomonis JD, et al. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003 Jul;306(1):387-93. [Content Brief]

[3]. Kanai Y, et al. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology. 2005 Dec;49(7):977-84. [Content Brief]

[4]. Nie C, et al. Study on chemical modification and analgesic activity of N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl) piperazine-1-carboxamide. Eur J Med Chem. 2020 May 15;194:112236. [Content Brief]

[5]. Tanaka H, et al. Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci. 2011 Mar 14;88(11-12):559-63. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6818 mL	13.4088 mL	26.8176 mL	67.0439 mL
	5 mM	0.5364 mL	2.6818 mL	5.3635 mL	13.4088 mL
	10 mM	0.2682 mL	1.3409 mL	2.6818 mL	6.7044 mL
	15 mM	0.1788 mL	0.8939 mL	1.7878 mL	4.4696 mL
	20 mM	0.1341 mL	0.6704 mL	1.3409 mL	3.3522 mL
	25 mM	0.1073 mL	0.5364 mL	1.0727 mL	2.6818 mL
	30 mM	0.0894 mL	0.4470 mL	0.8939 mL	2.2348 mL
	40 mM	0.0670 mL	0.3352 mL	0.6704 mL	1.6761 mL
	50 mM	0.0536 mL	0.2682 mL	0.5364 mL	1.3409 mL
	60 mM	0.0447 mL	0.2235 mL	0.4470 mL	1.1174 mL
	80 mM	0.0335 mL	0.1676 mL	0.3352 mL	0.8380 mL
	100 mM	0.0268 mL	0.1341 mL	0.2682 mL	0.6704 mL

BCTC Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BCTC393514-24-4TRP ChannelInsulin ReceptorCGRP ReceptorTransient receptor potential channelsCalcitonin gene-related peptide receptorNeuropathic painInflammatory painAnalgesiaProstate Cancer (PCa)Type 2 diabetesDU145Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

BCTC

Customer Review

BCTC Related Antibodies

3 Publications Citing Use of MCE BCTC

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TRP Channel Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

BCTC Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

BCTC Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report